iPSCs RNA silencing guide

iPSCs present unique biological barriers that cause conventional transfection to fail or trigger irreversible spontaneous differentiation:

Transfection-induced spontaneous differentiation destroys pluripotency

iPSCs maintain pluripotency under precise conditions; any stress can trigger differentiation. Cationic lipids and electroporation may trigger differentiation signaling in sensitive iPSC lines, causing upregulation of lineage markers (GATA4, GATA6, T/Brachyury) in some cases. Effect varies by iPSC line, reagent, and culture conditions. When differentiation occurs, downregulation of pluripotency factors (OCT4, SOX2 and NANOG expression falls) is observed. This can create heterogeneous cultures (some cells remain pluripotent, others partially differentiate) unsuitable for research requiring homogeneous populations or clinical applications requiring pure pluripotent cells.

Low lipofection efficiency with high cell death

iPSCs grow as compact colonies with strong E-cadherin-mediated cell-cell adhesion on basement membrane matrix. Lipoplexes must penetrate these tightly packed colonies, and interior cells receive minimal reagent. Edge cells show higher uptake but also higher death. The efficiency is often insufficient for population-level gene silencing studies; it can create mosaic colonies (some cells knocked down, others not) that confound interpretation.

Electroporation-induced anoikis and colony disruption

Electroporation requires single-cell dissociation (colonies must be dispersed to single cells for even exposure to electric pulse). This dissociation disrupts E-cadherin junctions that are critical for iPSC survival; loss of cell-cell contact triggers anoikis (detachment-induced apoptosis), potentially causing cell death. Surviving iPSCs often show reduced colony formation efficiency, altered morphology (flattened, spread-out instead of compact domes), and decreased pluripotency marker expression. The remaining colonies may show spontaneous differentiation. Electroporation can be fundamentally incompatible with colony-based iPSC biology.

Colony-based growth complicates reagent delivery

iPSCs grow as 3D dome-shaped colonies (100-500 μm diameter, multilayered) on basement membrane matrix-coated surfaces. Cells in colony interior are physically shielded from transfection reagents, which penetrate poorly beyond surface layers (1-2 cell layers deep). This creates gradient knockdown between the edge of a colony and its interior. Researchers often try to dissociate colonies for better reagent access, but dissociation triggers differentiation and anoikis. This creates a dilemma: maintain colony structure (poor transfection) or dissociate (induce death and differentiation).

Feeder-free culture sensitivity and matrix dependence

Modern iPSC culture uses feeder-free systems (basement membrane matrix substrate with defined pluripotency medium) to avoid mouse feeder contamination. iPSCs depend on basement membrane matrix (extract containing laminin, collagen IV, entactin) for survival signals via integrin receptors. Lipofection can damage matrix interactions; cationic lipids may disrupt integrin binding, causing cells to detach and undergo anoikis. Electroporation requires cells to be lifted from matrix, further disrupting these survival signals. After transfection, iPSCs may struggle to re-attach and re-establish colonies, so cells that initially survived electroporation may still be lost.

Viral integration risks and sustained transgene expression

Lentiviral and retroviral transduction integrates into the iPSC genome, creating permanent modifications unsuitable for disease modeling (alters patient genetic background) or clinical applications (FDA concerns about insertional mutagenesis). Even Sendai virus (non-integrating RNA virus used for reprogramming) can persist in iPSCs, causing sustained transgene expression that confounds experiments. Adeno-associated virus (AAV) shows variable iPSC transduction efficiency, which depends on the serotype, and epichromosomal persistence (weeks to months). For transient gene silencing studies, viral integration is unacceptable; only transient methods like ASOs enable reversible knockdown without genome modification.

Method comparison

Why AUMsilence™ sdASOs™ suit iPSCs

Key benefits

• Enables pluripotency network dissection
  Titrate OCT4, SOX2, NANOG knockdown to define minimal thresholds for pluripotency maintenance. A knockout is typically all or none, so it gives no graded reduction; ASO dose-response reveals functional thresholds.
• Directed differentiation optimization
  Knock down lineage-blocking factors (NOGGIN for mesoderm, DKK1 for endoderm, BMP4 for neuroectoderm) before differentiation protocols. Test temporal requirements without permanent gene loss.
• Patient-specific disease modeling
  Allele-specific knockdown of disease genes (HTT CAG expansion in Huntington, SOD1 mutations in ALS, APP/PSEN1 in Alzheimer) in patient iPSC-derived disease-relevant cell types (neurons, cardiomyocytes). Preserve patient genetic background.
• Epigenetic reprogramming studies
  Transiently knock down epigenetic modifiers (DNMT3A/3B, TET1/2/3, EZH2, KDM6A) during reprogramming or in established iPSCs. Study stage-specific requirements without permanent modifications.
• Post-reprogramming quality control
  Silence residual reprogramming transgenes (c-MYC, KLF4 from episomal or Sendai vectors) to reduce teratoma risk. Test if transgene-free iPSCs maintain pluripotency.
• Rapid timeline for hypothesis testing
  No viral vector cloning, no electroporation optimization. Seed iPSCs (Day -1), add AUMsilence sdASO (Day 0-4), validate knockdown and pluripotency (Day 2-4), perform functional assays (Day 4-14). Test gene function in 2 weeks.

Cell types and applications

• Feeder-free iPSCs (defined medium on basement membrane matrix): xeno-free systems
• Feeder-based iPSCs (MEF feeders): traditional culture
• Pluripotency network dissection (OCT4, SOX2, NANOG, KLF4, MYC)
• Directed differentiation protocol optimization (lineage-blocking factor knockdown)
• Patient-specific disease modeling (ALS, Huntington, Alzheimer, cardiomyopathies)
• Epigenetic reprogramming studies (DNMT, TET, PRC2, histone modifiers)
• Post-reprogramming safety (c-MYC, KLF4 silencing to reduce teratoma risk)
• iPSC-derived neurons, cardiomyocytes, hepatocytes, pancreatic β-cells
• Embryoid body (EB) differentiation studies
• iPSC genomic stability and quality control
• Naïve vs primed pluripotency studies (2i+LIF vs defined medium)
• Teaching labs and core facilities (reproducible iPSC manipulation)

• AUMsilence™ sdASO™

Alternative products

AUMsilence™ toASO™

• AUMsilence™ toASO™

Custom ASO design service

• Consult our scientists

Optimized protocols for feeder-free and feeder-based iPSC culture. No transfection reagents required.

Quick start protocol (feeder-free iPSCs)

1. 01Culture iPSCs on basement membrane matrix in defined pluripotency medium, passage at 80% confluency (EDTA or enzymatic dissociation)
2. 02Add AUMsilence™ sdASO™ directly to culture medium at 10 μM (no transfection reagent)
3. 03Incubate 48-96 hours at 37°C, 5% CO₂ with daily medium change (maintain pluripotency)
4. 04Validate knockdown by qRT-PCR (48-72h after treatment) and flow cytometry or immunofluorescence (72-96h after treatment)
5. 05Verify pluripotency preserved: OCT4+, SOX2+, NANOG+, SSEA-4+, TRA-1-60+ by flow or IF
6. 06Perform functional assays: embryoid body formation (trilineage differentiation), directed differentiation

Cell-type-specific protocols

Feeder-free iPSCs (defined medium on basement membrane matrix)

1. 01

   Step 1: iPSC culture maintenance

   Culture iPSCs on basement membrane matrix-coated plates (hESC-qualified matrix, diluted 1:100 in DMEM/F12, coat overnight at 4°C or 1h at 37°C). Use defined pluripotency medium (complete medium, no supplementation needed). Change medium daily because colonies are sensitive to pH and nutrient depletion. Passage at 70-80% confluency (every 4-6 days) using EDTA (0.5 mM, 3-5 min at 37°C) or enzymatic dissociation reagent (1:1 dilution, 1-2 min). Split 1:6 to 1:10. iPSCs grow as compact, dome-shaped colonies with sharp borders.
   Materials: Basement membrane matrix (hESC-qualified), defined pluripotency medium, EDTA or enzymatic dissociation reagent
   Note: Avoid over-confluency (>85%), which induces spontaneous differentiation. Monitor colony morphology daily: tight, dome-shaped with sharp edges indicates healthy pluripotent cells, while flat and spread-out morphology indicates differentiating cells.
   Maintain stock culture
2. 02

   Step 2: Seeding iPSCs for ASO treatment

   Passage iPSCs 24h before ASO treatment to ensure healthy, actively growing colonies. Seed at 30-50% confluency in 6-well plate (or desired format). Next day (Day 0), colonies should be ~50-60% confluent, which is optimal for ASO treatment. Colonies too sparse (<30%) or too dense (>80%) show reduced ASO uptake or increased stress.
   Materials: Standard iPSC culture materials
   Note: Timing is critical: ASO treatment works best on actively growing colonies (50-70% confluent), not freshly seeded single cells or over-confluent colonies.
   Day -1
3. 03

   Step 3: AUMsilence sdASO treatment of iPSCs

   At Day 0 (colonies 50-60% confluent), add AUMsilence sdASO directly to defined pluripotency medium at 10 μM final concentration. For 2 mL medium in 6-well, add 20 μL of 1 mM AUMsilence sdASO stock. Do not switch to a reduced or starvation medium for the treatment: AUMsilence sdASOs are added to the complete medium. Change medium daily with fresh medium + AUMsilence sdASO (re-dose daily to maintain 10 μM; ASO not degraded but diluted by medium change).
   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)
   Note: Daily medium change is required for iPSC health because defined medium exhausts nutrients and buffers within 24h. Re-add AUMsilence sdASO with each change. Cellular uptake begins within 6-12h of addition and accumulates over 48-96h.
   Day 0
4. 04

   Step 4: Incubation and monitoring (preserve pluripotency)

   Incubate 48-96 hours at 37°C, 5% CO₂ with daily medium change. Monitor colony morphology daily by phase-contrast microscopy: colonies should maintain dome shape, tight packing, sharp borders. If colonies flatten or show differentiation (darkened centers, spread edges), reduce ASO concentration or shorten treatment.
   Materials: Humidified CO₂ incubator
   Note: Compare colony morphology with untreated control colonies side by side.
   Days 0-4
5. 05

   Step 5: Validation of knockdown and pluripotency

   At 48-72h after treatment: qRT-PCR for target mRNA knockdown, expect 70-95% knockdown, and for the pluripotency markers (OCT4, SOX2, NANOG) read against untreated iPSCs. At 72-96h: Protein validation by (1) Flow cytometry: dissociate colonies to single cells (cell dissociation reagent, 5-10 min), stain for surface markers SSEA-4-PE, TRA-1-60-APC, TRA-1-81-FITC, and viability dye. (2) Immunofluorescence: fix colonies, permeabilize, stain for OCT4, SOX2, NANOG (nuclear), SSEA-4 (surface). Read the staining across each colony.
   Materials: RNA extraction kit, qPCR reagents, cell dissociation reagent, flow antibodies (SSEA-4, TRA-1-60, TRA-1-81), IF antibodies (OCT4, SOX2, NANOG)
   Note: For intracellular targets (transcription factors), use IF or Western blot. For surface targets, use flow cytometry. Read the pluripotency markers against untreated iPSCs; a reduction indicates differentiation.
   Days 2-4
6. 06

   Step 6: Functional validation: Embryoid body formation

   Gold standard assay for pluripotency. At 72-96h post-ASO, passage iPSCs, dissociate to small clumps (enzymatic dissociation or EDTA, minimal dissociation), seed in ultra-low attachment plates in defined medium without bFGF (or EB formation medium). Cultures spontaneously form floating spherical embryoid bodies (EBs). After 7-14 days, harvest EBs, extract RNA, measure trilineage markers by qRT-PCR: Ectoderm (PAX6, TUBB3, NCAM), Mesoderm (T/BRACHYURY, MESP1, HAND1), Endoderm (SOX17, FOXA2, AFP). Read the three lineages in the embryoid bodies; where the target is required for pluripotency or for differentiation, a skewed or absent set is the expected phenotype.
   Materials: Ultra-low attachment plates, EB formation medium, qPCR primers for lineage markers
   Note: EB formation tests pluripotency maintenance during ASO treatment. If target gene is pluripotency factor (OCT4, SOX2, NANOG), expect defective EB formation or skewed lineage (part of experimental validation).
   Days 3-17

iPSCs on feeders (mouse embryonic fibroblasts)

1. 01

   Step 1: MEF feeder preparation

   Culture mitotically inactivated mouse embryonic fibroblasts (MEFs) as feeder layer. Irradiate MEFs (40 Gy) or treat with mitomycin C (10 μg/mL, 2-3h) to arrest division. Seed at 5 × 10⁴ cells/cm² on gelatin-coated plates. Use within 7 days.
   Materials: Mitotically inactivated MEFs, gelatin-coated plates
   Note: For feeder-free culture, use basement membrane matrix instead.
   Day -1 (prepare feeders day before seeding iPSCs)
2. 02

   Step 2: iPSC culture on MEFs

   Culture iPSCs on MEF feeders in hESC medium (DMEM/F12 + 20% serum replacement + bFGF 10 ng/mL + NEAA + stable glutamine supplement + β-mercaptoethanol). Change medium daily. Passage with collagenase IV (1 mg/mL, 5-10 min) to preserve colony structure, or enzymatic dissociation for single-cell passaging with ROCK inhibitor (10 μM).
   Materials: hESC medium, bFGF, collagenase IV or enzymatic dissociation reagent, ROCK inhibitor
   Note: Feeder-based culture has higher spontaneous differentiation rate than feeder-free. Monitor morphology closely.
   Maintain stock culture
3. 03

   Step 3: AUMsilence sdASO treatment on MEF feeders

   Add AUMsilence sdASO at 10 μM to iPSCs on MEF feeders. MEFs also take up ASO (fibroblasts are adherent cells with gymnotic uptake capability), but this does not affect iPSC studies; MEFs are post-mitotic, inert support layer. Change medium daily with fresh ASO. Validate knockdown specifically in iPSCs by manual colony picking or FACS enrichment (TRA-1-60+ sorting to isolate iPSCs from MEFs before analysis).
   Materials: AUMsilence sdASO
   Note: For most targets, knockdown in MEFs irrelevant. For cross-contamination concerns, switch to feeder-free basement membrane matrix culture.
   Days 0-4

Directed differentiation with ASO pre-treatment

1. 01

   Step 1: Identify lineage-blocking genes

   For mesoderm differentiation (cardiomyocytes, blood): BMP antagonists (NOGGIN, CHORDIN) can block mesoderm at specific stages; knockdown may enhance efficiency. For endoderm differentiation (hepatocytes, pancreas): WNT inhibitors (DKK1) or neural inducers (SOX1) may block endoderm; test knockdown. For neuroectoderm: BMP4 blocks neural, WNT blocks anterior neural; knockdown timing critical.
   Materials: Literature review for differentiation protocol optimization
   Note: Approach: Treat iPSCs with AUMsilence sdASO targeting blocking factor (e.g., NOGGIN ASO, 48h), then initiate differentiation protocol. Compare efficiency to control.
   Design phase
2. 02

   Step 2: Cardiomyocyte differentiation example

   Cardiomyocyte protocol: Day -2: Seed iPSCs at 80% confluency. Day 0: Add AUMsilence sdASO targeting NOGGIN (10 μM, optional; tests if BMP antagonist blockade enhances mesoderm). Day 2: Start cardiac differentiation: WNT activator small molecule (6-12 μM, 24h) to induce mesoderm. Day 3: WNT inhibitor small molecule (5 μM, 48h) to specify cardiac mesoderm. Day 8-10: Spontaneous beating cardiomyocytes appear. Measure cardiac markers (TNNT2, MYH6, NKX2-5) by qRT-PCR and immunofluorescence.
   Materials: WNT pathway small molecules, cardiac differentiation medium
   Note: ASO knockdown can be combined with differentiation protocols to test gene requirements at each stage.
   Days -2 to 10

Disease modeling: Patient iPSC-neurons with gene knockdown

1. 01

   Step 1: Patient iPSC line validation

   Use patient-derived iPSCs carrying disease mutation: ALS (SOD1 A4V, TDP-43, FUS), Huntington (HTT CAG expansion >40 repeats), Alzheimer (APP, PSEN1 mutations). Validate pluripotency (OCT4, SOX2, NANOG by IF, SSEA-4/TRA-1-60 by flow, normal karyotype). Confirm mutation present (Sanger sequencing or qPCR).
   Materials: Patient iPSC line, sequencing primers
   Note: Isogenic control lines (CRISPR-corrected) serve for comparison but are not required; compare to healthy donor iPSCs.
   Baseline characterization
2. 02

   Step 2: Neuronal differentiation (dual SMAD inhibition)

   Differentiate iPSCs to neuroectoderm: Dual SMAD inhibition (BMP inhibitor + TGF-β/Activin inhibitor, 10-14 days) generates neural progenitors (PAX6+, SOX1+). Pattern to motor neurons (add retinoic acid + Sonic Hedgehog agonist, 10-14 days) for ALS. Pattern to striatal neurons (BDNF, Dkk1, 14-21 days) for Huntington. Pattern to cortical neurons (BDNF, GDNF, 21-35 days) for Alzheimer. Terminal differentiation: 21-60 days total to mature neurons (MAP2+, TUBB3+, synapsin+).
   Materials: BMP and TGF-β pathway inhibitors, neural differentiation media, patterning factors
   Note: Disease phenotypes appear at maturation stage: ALS motor neurons show TDP-43 aggregates, reduced survival. Huntington striatal neurons show HTT aggregates, increased apoptosis.
   Days 0-60
3. 03

   Step 3: Allele-specific knockdown in diseased neurons

   At neuronal maturity (Day 30-60), add AUMsilence sdASO targeting mutant allele: HTT allele-specific ASO (targets CAG expansion), SOD1 mutation-specific ASO, or APP/PSEN1 knockdown. Incubate 72-96h. Measure rescue of disease phenotype: (1) Protein aggregation: immunofluorescence for HTT, TDP-43, or Aβ aggregates (expect reduction). (2) Cell survival: viability assay, caspase-3 activation (expect improved survival). (3) Neuronal function: electrophysiology (patch-clamp), calcium imaging (expect improved activity).
   Materials: Allele-specific AUMsilence sdASO, disease phenotype assays
   Note: Allele-specific targeting requires SNP or mutation-specific ASO design. Contact AUM for custom design.
   Days 30-65

Essential controls for iPSC experiments

• Untreated iPSCs: Baseline pluripotency markers, colony morphology, differentiation potential
  Culture identically but without ASO. Critical for verifying no spontaneous differentiation from ASO treatment.
• Non-targeting control ASO: Control for non-specific ASO effects on pluripotency
  Use AUM non-targeting control at 10 μM. Measure OCT4, SOX2, NANOG, SSEA-4; these should match untreated levels.
• Differentiation positive control: Validate differentiation capacity preserved
  Perform embryoid body formation or directed differentiation in parallel with ASO-treated cells. If both produce similar lineage markers, pluripotency preserved.
• Lipofection comparison: Optional. Compare AUMsilence sdASO with lipofection in the same experiment
  Treat iPSCs with lipofection reagent. Measure lineage markers (GATA6, T, PAX6) at 24-48h, which can rise, and pluripotency markers, which can fall, against AUMsilence sdASO-treated iPSCs cultured in parallel.

Optimization strategies for iPSC applications

• ASO concentration
  Recommendation: The recommended working range is 5-20 μM, with a starting concentration of 10 μM.
  Rationale: The optimal concentration varies with the target gene, the RNA class (messenger RNA, microRNA or long non-coding RNA) and the cell type, and should be determined by titration for each system. Watch colony morphology as you go.
• Treatment duration
  Recommendation: 48-72h for mRNA validation, 72-96h for protein validation. Extend to 96h for long half-life proteins. Do not exceed 96h unless testing long-term effects.
  Rationale: Prolonged ASO exposure (>96h) not necessary due to non-dividing nature and accumulation over time. Daily re-dosing maintains levels.
• Colony confluency
  Recommendation: Treat at 50-70% confluency. Avoid <30% (stressed, sparse) or >80% (over-confluent, spontaneous differentiation).
  Rationale: Actively growing colonies at optimal density show best ASO uptake and maintain pluripotency throughout treatment.
• Daily medium change with re-dosing
  Recommendation: Change defined pluripotency medium daily, re-add AUMsilence sdASO each time (10 μM fresh). This maintains pH, nutrients, and ASO concentration.
  Rationale: iPSCs require daily medium change for health. ASO is stable but diluted by medium replacement; re-dosing maintains knockdown.

Validation covers the target transcript, the pluripotency markers, the lineage markers, colony morphology and trilineage differentiation. Where the target is itself a pluripotency factor, a loss of these readouts is the expected phenotype.

Immunofluorescence for pluripotency markers

Flow cytometry for pluripotency surface markers

qRT-PCR for pluripotency and lineage markers

Alkaline phosphatase staining (quick pluripotency assessment)

Embryoid body (EB) formation and trilineage differentiation

Critical controls for iPSC validation

• Untreated iPSCs
  Purpose: Baseline for pluripotency markers, colony morphology, differentiation capacity
  Culture identically but without ASO. Compare OCT4/SOX2/NANOG levels, SSEA-4/TRA-1-60 percentage, colony morphology. Should match ASO-treated (non-targeting control) exactly if pluripotency preserved.
• Non-targeting control ASO
  Purpose: Control for non-specific ASO effects on pluripotency
  Use AUM non-targeting control at 10 μM with same treatment schedule (daily re-dosing). Measure pluripotency markers; should match untreated. If non-targeting ASO causes differentiation (OCT4/SOX2 reduction, lineage marker upregulation), indicates an ASO chemistry issue.
• Differentiation positive control
  Purpose: Validate that assays detect loss of pluripotency
  Treat parallel iPSC culture with differentiation inducers: BMP4 (50 ng/mL, 24-48h) induces trophectoderm (CDX2+, EOMES+), retinoic acid (1 μM, 48h) induces differentiation and reduces pluripotency. Measure OCT4/SOX2/NANOG (expect reduction), SSEA-4/TRA-1-60 (expect <50% positive), lineage markers (expect upregulation). Confirms assays sensitive to differentiation.
• Embryoid body formation from ASO-treated iPSCs
  Purpose: Functional validation that pluripotency capacity maintained
  Generate EBs from untreated iPSCs, non-targeting control ASO-treated iPSCs, and experimental ASO-treated iPSCs (unless targeting pluripotency factor itself). All three should form EBs and express trilineage markers equally. If experimental ASO iPSCs fail EB formation or show skewed lineage, indicates pluripotency compromise.